R J Colonno

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi request reprint Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection
    R J Colonno
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492 7660, USA
    J Infect Dis 184:1236-45. 2001
  2. ncbi request reprint Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
    Richard J Colonno
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
    Hepatology 44:1656-65. 2006
  3. ncbi request reprint Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens
    Richard Colonno
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut, USA
    J Infect Dis 189:1802-10. 2004
  4. pmc Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
    E V Genovesi
    Pharmaceutical Research Institute, Bristol Myers Squibb, Wallingford, Connecticut 06492, USA
    Antimicrob Agents Chemother 42:3209-17. 1998
  5. ncbi request reprint Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatitis B virus (HBV) infection
    E V Genovesi
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, Connecticut, CT 06492 7660, USA
    Antiviral Res 48:197-203. 2000
  6. pmc Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase
    D J Tenney
    Department of Virology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA
    Antimicrob Agents Chemother 41:2680-5. 1997
  7. pmc Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
    D J Tenney
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Pkwy, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 48:3498-507. 2004
  8. pmc Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
    G Yamanaka
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492 7660, USA
    Antimicrob Agents Chemother 43:190-3. 1999
  9. pmc Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro
    S Levine
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 46:2525-32. 2002
  10. pmc De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus
    G Luo
    Department of Virology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492 7660, USA
    J Virol 74:851-63. 2000

Collaborators

Detail Information

Publications29

  1. ncbi request reprint Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection
    R J Colonno
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492 7660, USA
    J Infect Dis 184:1236-45. 2001
    ..ETV was well tolerated, and there was no evidence of resistant variants. On the basis of historical data, long-term ETV treatment appeared to significantly prolong the life of treated animals and delay the emergence of HCC...
  2. ncbi request reprint Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
    Richard J Colonno
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
    Hepatology 44:1656-65. 2006
    ..These findings suggest that the rapid, sustained suppression of HBV replication, combined with a requirement for multiple substitutions, creates a high genetic barrier to ETVr in nucleoside naïve patients...
  3. ncbi request reprint Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens
    Richard Colonno
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut, USA
    J Infect Dis 189:1802-10. 2004
    ..The unique I50L substitution is the signature mutation for resistance to ATV...
  4. pmc Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
    E V Genovesi
    Pharmaceutical Research Institute, Bristol Myers Squibb, Wallingford, Connecticut 06492, USA
    Antimicrob Agents Chemother 42:3209-17. 1998
    ..These results indicate that BMS-200475 should be evaluated in clinical trials for the therapy of chronic human hepatitis B virus infections...
  5. ncbi request reprint Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatitis B virus (HBV) infection
    E V Genovesi
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, Connecticut, CT 06492 7660, USA
    Antiviral Res 48:197-203. 2000
    ..These results indicated that the minimally effective antiviral daily per os dose of lobucavir in WHV-carrier woodchucks was approximately 5 mg/kg...
  6. pmc Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase
    D J Tenney
    Department of Virology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA
    Antimicrob Agents Chemother 41:2680-5. 1997
    ..Furthermore, LBV may be effective in the treatment of GCV-resistant HCMV...
  7. pmc Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
    D J Tenney
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Pkwy, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 48:3498-507. 2004
    ..In summary, infrequent ETV resistance can emerge during prolonged therapy, with selection of additional RT substitutions within a 3TC(r) HBV background, leading to reduced ETV susceptibility and treatment failure...
  8. pmc Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
    G Yamanaka
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492 7660, USA
    Antimicrob Agents Chemother 43:190-3. 1999
    ..Compared with five other nucleoside analogs of medical interest (lamivudine, penciclovir, ganciclovir, acyclovir, and lobucavir), BMS-200475 was most efficiently phosphorylated to the triphosphate in HepG2 cells...
  9. pmc Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro
    S Levine
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 46:2525-32. 2002
    ..These findings are predictive of potent antiviral activity of ETV against both wild-type and 3TC-resistant HBV...
  10. pmc De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus
    G Luo
    Department of Virology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492 7660, USA
    J Virol 74:851-63. 2000
    ..These findings suggest that HCV NS5B is able to initiate RNA synthesis de novo...
  11. pmc Separate functional domains of the herpes simplex virus type 1 protease: evidence for cleavage inside capsids
    B J Robertson
    Department of Virology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492 7660, USA
    J Virol 70:4317-28. 1996
    ..Our results demonstrate that the HSV-1 protease has distinct functional domains and some of these functions can complement in trans...
  12. ncbi request reprint Stavudine resistance: an update on susceptibility following prolonged therapy
    P F Lin
    Bristol Myers Squibb, Wallingford, Conn, USA
    Antivir Ther 4:21-8. 1999
    ..This low incidence of stavudine resistance is in striking contrast to that observed with other nucleoside analogues and further supports the use of stavudine in first-line combination therapy for HIV patients...
  13. pmc Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition
    Charles E Mazzucco
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 52:598-605. 2008
    ..In summary, cell culture and enzymatic studies yielded no evidence that would predict mitochondrial toxicity of ETV at exposure levels in excess of those expected to be achieved clinically...
  14. pmc Inhibition of hepatitis B virus polymerase by entecavir
    David R Langley
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06443, USA
    J Virol 81:3992-4001. 2007
    ..Overall, these studies explain the potency, mechanism, and cross-resistance profile of ETV against HBV and account for the successful treatment of naive and LVD- or ADV-experienced chronic HBV patients...
  15. pmc Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present
    Daniel J Tenney
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Antimicrob Agents Chemother 51:902-11. 2007
    ..In summary, ETV was effective in LVD-refractory patients, with resistant sequences arising from a subset of patients harboring preexisting LVDr/ETVr variants and with approximately half of the patients experiencing a virologic rebound...
  16. ncbi request reprint The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons
    Michael Giordano
    Pharmaceutical Research Institute, Bristol Myers Squibb Company, 3 rue Joseph Monier, 92500 Rueil Malmaison, Paris, France
    J Clin Virol 35:420-5. 2006
    ..However, a variety of factors can confound these comparisons, resulting in misleading or invalid conclusions...
  17. doi request reprint Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response
    Carl J Baldick
    Bristol Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA
    J Hepatol 48:895-902. 2008
    ..Using >500 patient HBV isolates from several entecavir clinical trials, we show that phenotypic susceptibility correlates with genotypic resistance and patient virologic responses...
  18. ncbi request reprint Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion
    Ronald S Veazey
    Tulane National Primate Research Center, Covington, Louisiana 70433, USA
    Nature 438:99-102. 2005
    ..In vivo, significant protection was achieved using each compound alone and in combinations. CMPD167 and BMS-378806 were protective even when applied 6 h before challenge...
  19. ncbi request reprint A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients
    Ting Tsung Chang
    National Cheng Kung University Medical College, Tainan, Taiwan
    Gastroenterology 129:1198-209. 2005
    ..This randomized, dose-ranging, phase 2 study compared the efficacy and safety of entecavir with lamivudine in lamivudine-refractory patients...
  20. pmc Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors
    Joseph Yanchunas
    Gene Expression and Protein Biochemistry Department, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543 4000, USA
    Antimicrob Agents Chemother 49:3825-32. 2005
    ..The results of this study provide a molecular understanding of the novel hypersusceptibility of atazanavir-resistant I50L/A71V-containing clinical isolates to other currently approved PIs...
  21. pmc Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication
    Patricia L Marion
    Division of Gastroenterology, Stanford University School of Medicine, Stanford, California 94305 5187, USA
    Antimicrob Agents Chemother 46:82-8. 2002
    ..ETV and 3TC were both well tolerated in all treated animals. These results show that ETV is a highly potent and effective antiviral in the DHBV duck model...
  22. pmc Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors
    Richard J Colonno
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA
    Antimicrob Agents Chemother 47:1324-33. 2003
    ..0-fold), the presence of at least five of these substitutions correlated strongly with loss of atazanavir susceptibility. Mutations associated with reduced susceptibility to each of the other six PIs were also determined...
  23. pmc Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection
    Wendy K Foster
    School of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia 5005, Australia
    Antimicrob Agents Chemother 47:2624-35. 2003
    ....
  24. ncbi request reprint Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus
    Justin G Julander
    Institute for Antiviral Research, Animal, Dairy, and Veterinary Sciences Department and Biotechnology Center, Utah State University, 4700 Old Main Hill, Logan, UT 84322 4700, USA
    Antiviral Res 59:155-61. 2003
    ..ETV was well tolerated and no morbidity or mortality was observed during the 10-day study. Similar to other animal models, ETV displayed potent anti-HBV activity in this transgenic mouse model...
  25. doi request reprint Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance
    Carl J Baldick
    Bristol Myers Squibb Research and Development, Wallingford, CT 06492, USA
    Hepatology 47:1473-82. 2008
    ....
  26. ncbi request reprint Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability
    Kuo Long Yu
    Department of Chemistry, The Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Bioorg Med Chem Lett 17:895-901. 2007
    ....
  27. pmc Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions
    Qi Guo
    Department of Virology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA
    J Virol 77:10528-36. 2003
    ..BMS-378806 therefore serves as a prototype for this new class of antiretroviral agents and validates gp120 as a viable target for small-molecule inhibitors...
  28. pmc Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection
    Wendy K Foster
    Hepatitis Virus Research Laboratory, Infectious Diseases Laboratories, Institute of Medical and Veterinary Science, Frome Rd, Box 14 Rundle Mall, Adelaide, SA 5000, Australia
    J Virol 79:5819-32. 2005
    ..Since DHBV infection of ducks provides a good model system for HBV infection in humans, it seems likely that ETV may be useful in postexposure therapy for HBV infection aimed at preventing the development of persistent infection...
  29. ncbi request reprint Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions
    Tao Wang
    Department of Discovery Chemistry, The Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA
    J Med Chem 46:4236-9. 2003
    ..The 7-azaindole derivative 3, BMS-378806, exhibited improved pharmaceutical properties while retaining the HIV-1 inhibitory profile of 2...